# Loki Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/loki-therapeutics

- Industry: Biotechnology
- Headquarters: Brooklyn, US
- Website: www.lokitx.com
- Latest round: Seed (Jan 25, 2022)
- Investors on record: 1

## About

Based in Brooklyn, US, and founded in 2017, Loki Therapeutics Inc develops next-generation therapeutics that leverage vaccination recall antigens to improve longevity and treat immune-system-related diseases by delivering vaccine recall antigens to tumor cells with genetically attenuated bacterial vectors. The company was co-founded by Christopher Bradley (CEO) and Claudia Gravekamp. In January 2022, Loki Therapeutics raised seed funding led by investor Formic Ventures. 

The company's pipeline includes several preclinical programs that target various types of cancer, including lung cancer, melanoma, and breast cancer. It uses an approach that harnesses childhood memory T cells to fight cancer. Their AWAKE technology activates and redirects pre-existing memory T cells created during childhood to target cancer cells.

## Funding rounds

- Seed, Jan 25, 2022 — Formic Ventures

## Investors

- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Seed